{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:41:03Z","timestamp":1767177663174,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012987","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000}}],"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Walter Fischli Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00c3\u00b6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030-236279 and CRSII5_183536"],"award-info":[{"award-number":["320030-236279 and CRSII5_183536"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    Chagas disease, caused by the parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    , affects millions of people globally. Unfortunately, the available treatment options, especially for the chronic stage of the disease, are suboptimal. Given the chronic nature of the disease and the elusive nature of the parasite, there is a high need for new and safer drugs that deliver sterile cure. Posaconazole was a promising lead in the drug discovery pipeline but ultimately failed in clinical trials due to patient relapses. This failure illustrates the need for a drug screening assay that can predict sterile cure by assessing recrudescence after treatment. Here, we used human induced pluripotent stem cell (iPSC)-derived macrophages (iMACs) as host cells for\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    . The iMACs were highly susceptible to infection by the parasites. By combining red fluorescent protein (RFP)-expressing iMACs with mNeonGreen-expressing\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    , we were able to monitor the dynamics of the infection through live cell imaging. The activity of the compounds benznidazole and posaconazole was consistent with the results of an established infection system using mouse primary macrophages. The post-mitotic nature of iMACs makes them suitable host cells for long-term assays needed to assess recrudescence of parasites. Moreover, their human origin, stable genetic background, and capacity for genetic modification make the iMACs excellent host cells for studying host-pathogen interaction.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0012987","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:46:11Z","timestamp":1761327971000},"page":"e0012987","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Induced pluripotent stem cell-derived human macrophages as an infection model for Trypanosoma cruzi"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6060-9081","authenticated-orcid":true,"given":"Lore","family":"Baert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Cal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Doll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-1941","authenticated-orcid":true,"given":"Pascal","family":"M\u00e4ser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"pntd.0012987.ref001","unstructured":"World Health Organization. Chagas disease (also known as American trypanosomiasis). 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis)"},{"issue":"2","key":"pntd.0012987.ref002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4269\/ajtmh.14-0238","article-title":"Evidence of autochthonous Chagas disease in southeastern Texas","volume":"92","author":"MN Garcia","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0012987.ref003","doi-asserted-by":"crossref","first-page":"e210151","DOI":"10.1590\/0074-02760210151","article-title":"Population movements, borders, and Chagas disease","volume":"117","author":"A Avaria","year":"2022","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"9723","key":"pntd.0012987.ref004","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"A Rassi","year":"2010","journal-title":"Lancet"},{"key":"pntd.0012987.ref005","unstructured":"CDC. Clinical care of Chagas disease. 2024. https:\/\/www.cdc.gov\/chagas\/hcp\/clinical-care\/index.html"},{"issue":"20","key":"pntd.0012987.ref006","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"I Molina","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"pntd.0012987.ref007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2018.1417380","article-title":"Phenotypic screening approaches for Chagas disease drug discovery","volume":"13","author":"E Chatelain","year":"2018","journal-title":"Expert Opin Drug Discov"},{"key":"pntd.0012987.ref008","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1051\/parasite\/2014040","article-title":"Mammalian cellular culture models of Trypanosoma cruzi infection: a review of the published literature","volume":"21","author":"GA Duran-Rehbein","year":"2014","journal-title":"Parasite"},{"issue":"4","key":"pntd.0012987.ref009","doi-asserted-by":"crossref","first-page":"e0004584","DOI":"10.1371\/journal.pntd.0004584","article-title":"Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade","volume":"10","author":"M De Rycker","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0012987.ref010","doi-asserted-by":"crossref","first-page":"e0008487","DOI":"10.1371\/journal.pntd.0008487","article-title":"Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas\u2019 disease drug discovery","volume":"14","author":"AF Fesser","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0012987.ref011","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1128\/AAC.01777-09","article-title":"Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas\u2019 disease","volume":"54","author":"JC Engel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0012987.ref012","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2016.08.003","article-title":"Assessing anti-T. cruzi candidates in vitro for sterile cidality","volume":"6","author":"M Cal","year":"2016","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1","key":"pntd.0012987.ref013","doi-asserted-by":"crossref","first-page":"e0011559","DOI":"10.1371\/journal.pntd.0011559","article-title":"Induced pluripotent stem cell-derived human macrophages as an infection model for Leishmania donovani","volume":"18","author":"L Baert","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0012987.ref014","doi-asserted-by":"crossref","first-page":"103434","DOI":"10.1016\/j.isci.2021.103434","article-title":"STING regulates peripheral nerve regeneration and colony stimulating factor 1 receptor (CSF1R) processing in microglia","volume":"24","author":"G Morozzi","year":"2021","journal-title":"iScience"},{"issue":"1","key":"pntd.0012987.ref015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41598-018-20064-2","article-title":"Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo","volume":"8","author":"OM Russell","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"pntd.0012987.ref016","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00436-001-0511-5","article-title":"An anti-contamination cocktail for the in vitro isolation and cultivation of parasitic protozoa","volume":"88","author":"P M\u00e4ser","year":"2002","journal-title":"Parasitol Res"},{"issue":"10","key":"pntd.0012987.ref017","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3390\/pathogens12101217","article-title":"Trypanosoma cruzi STIB980: A TcI Strain for Drug Discovery and Reverse Genetics","volume":"12","author":"A Fesser","year":"2023","journal-title":"Pathogens"},{"issue":"2","key":"pntd.0012987.ref018","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/tropicalmed4020082","article-title":"Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection","volume":"4","author":"CH Franco","year":"2019","journal-title":"Trop Med Infect Dis"},{"issue":"7","key":"pntd.0012987.ref019","doi-asserted-by":"crossref","first-page":"e0006612","DOI":"10.1371\/journal.pntd.0006612","article-title":"Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas\u2019 disease drug discovery","volume":"12","author":"LM MacLean","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0012987.ref020","doi-asserted-by":"crossref","first-page":"165707","DOI":"10.1016\/j.bbadis.2020.165707","article-title":"Signaling pathways that regulate Trypanosoma cruzi infection and immune response","volume":"1866","author":"FM Cerb\u00e1n","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"pntd.0012987.ref021","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/pathogens12020282","article-title":"A Review on the Immunological Response against Trypanosoma cruzi","volume":"12","author":"G Macaluso","year":"2023","journal-title":"Pathogens"},{"issue":"1","key":"pntd.0012987.ref022","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1038\/s41598-021-82137-z","article-title":"Genome-wide CRISPR\/Cas9-knockout in human induced Pluripotent Stem Cell (iPSC)-derived macrophages","volume":"11","author":"E Navarro-Guerrero","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"pntd.0012987.ref023","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.micinf.2018.03.002","article-title":"Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease","volume":"20","author":"L da Silva Lara","year":"2018","journal-title":"Microbes and Infection"},{"issue":"6","key":"pntd.0012987.ref024","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.stemcr.2019.04.017","article-title":"Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection","volume":"12","author":"A Bozzi","year":"2019","journal-title":"Stem Cell Reports"},{"issue":"8","key":"pntd.0012987.ref025","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging","volume":"59","author":"AF Francisco","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pntd.0012987.ref026","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.stemcr.2020.12.017","article-title":"Generation of Human-Induced Pluripotent Stem Cell-Derived Functional Enterocyte-Like Cells for Pharmacokinetic Studies","volume":"16","author":"S Yoshida","year":"2021","journal-title":"Stem Cell Reports"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012987","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:44:42Z","timestamp":1763405082000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012987"}},"subtitle":[],"editor":[{"given":"Erica","family":"Silberstein","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012987","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}